New Ways to Attack Atopic Dermatitis: Realm Expects POC Next Quarter
Realm Therapeutics is evaluating a substance derived from insights into innate immunity that has potential as an immunomodulator in various dermatological disorders, including atopic dermatitis and acne, with proof-of-concept (POC) expected in the third quarter.
You may also be interested in...
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
An ultra-fast-acting allergy immunotherapy to induce tolerance to house dust mites is being sought in a collaboration between two Swiss biotechs, Anergis and Virometix.
Emerging Company Profile: Austria’s OncoOne could have an anticancer biologic which targets oxidized macrophage migration inhibitor factor ready for the clinic in around two years.